An Overview on Prenatal Screening for Chromosomal Aberrations

Journal of Laboratory Automation

Volumn 20, Issue 5, 2015, Pages 562-573

  Hixson, Lucas ^a   Goel, Srishti ^a   Schuber, Paul ^a   Faltas, Vanessa ^a   Lee, Jessica ^a   Narayakkadan, Anjali ^a   Leung, Ho ^a   Osborne, Jim ^a  

^a KECK GRADUATE INSTITUTE   (United States)

Author keywords

aneuploidy; chromosomes; Down syndrome; next generation sequencing; screening; trisomy

Indexed keywords

CHROMOSOMES; OBSTETRICS; SCREENING; TURNAROUND TIME;

ANEUPLOIDY; CHROMOSOMAL ABERRATION; CURRENT DIAGNOSTICS; DOWN SYNDROME; NEXT-GENERATION SEQUENCING; SENSITIVITY AND SPECIFICITY; TECHNOLOGICAL CHARACTERISTICS; TRISOMY;

GENE ENCODING;

ABORTION; AMNIOCENTESIS; ANEUPLOIDY; ANXIETY; CHORION VILLUS SAMPLING; CHROMOSOME ANALYSIS; CORDOCENTESIS; DOWN SYNDROME; ECHOCARDIOGRAPHY; FETUS KARYOTYPING; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; MATERNAL SERUM SCREENING TEST; MICROARRAY ANALYSIS; NEXT GENERATION SEQUENCING; NUCHAL TRANSLUCENCY MEASUREMENT; POLYMERASE CHAIN REACTION; PRENATAL SCREENING; QUANTITATIVE FLUORESCENCE POLYMERASE CHAIN REACTION; RAPID TEST; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; SPONTANEOUS ABORTION; TURNAROUND TIME; VALIDATION PROCESS; ADVERSE EFFECTS; BLOOD; CHEMISTRY; CHROMOSOME ABERRATION; CHROMOSOME DISORDERS; DNA SEQUENCE; EMBRYOLOGY; FEMALE; FETOMATERNAL TRANSFUSION; GENETIC SCREENING; HIGH THROUGHPUT SEQUENCING; KARYOTYPING; LABORATORY AUTOMATION; PREGNANCY; PRENATAL DIAGNOSIS; TRENDS;

DNA;

ANEUPLOIDY; AUTOMATION, LABORATORY; CHROMOSOME ABERRATIONS; CHROMOSOME DISORDERS; DNA; FEMALE; GENETIC TESTING; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; KARYOTYPING; MATERNAL SERUM SCREENING TESTS; MATERNAL-FETAL EXCHANGE; PREGNANCY; PRENATAL DIAGNOSIS; SEQUENCE ANALYSIS, DNA;

EID: 84941918030     PISSN: 22110682     EISSN: 22110690     Source Type: Journal    
DOI: 10.1177/2211068214564595     Document Type: Review

References (79)

1. M.DeyS.SharmaS.AggarwalPrenatal Screening Methods for Aneuploidies. North Am. J. Med. Sci. 2013, 5, 182–190.
2. D.CiminiF.DegrassiAneuploidy: A Matter of Bad Connections. Trends Cell Biol. 2005, 15, 442–451.
3. T.HassoldH.HallP.HuntThe Origin of Human Aneuploidy: Where We Have Been, Where We Are Going. Hum. Mol. Genet. 2007, 16, 203–208.
4. J.RovetteTurner Syndrome: Genetic and Hormonal Factors Contributing to a Specific Learning Disability Profile. Learn. Disabil. Res. Pract. 2004, 19, 133–145.
5. S.MunneJ.CohenChromosome Abnormalities in Human Embryos. Hum. Reprod. Update1998, 4, 842–855.
6. Centers for Disease Control and Prevention. Key Findings: Prevalence of Down Syndrome in the United States. http://www.cdc.gov/ncbddd/birthdefects/features/key-findings-down-syndrome-prevalence.html
7. A.CeredaJ.CareyThe Trisomy 18 Syndrome. Orphanet J. Rare Dis. 2012, 7, 1–14.
8. American Accreditation HealthCare Commission. Trisomy 13–Patau Syndrome. http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002625/
9. S.GirirajanParental-Age Effects in Down Syndrome (Commentary on L.S. Penrose J. Genet). J. Genet. 2009, 88, 1–7.
10. J.HaddowG.PalomakiG.Knight. Prenatal Screening for Down’s Syndrome with Use of Maternal Serum Markers. N. Engl. J. Med. 1992, 327, 588–593.
11. American Accreditation HealthCare Commission. Karyo-typing. http://www.nlm.nih.gov/medlineplus/ency/article/003935.htm
12. L.ZhangX.H.ZhangM.Y.Liang. Prenatal Cytogenetic Diagnosis Study of 2782 Cases of High-Risk Pregnant Women. Chin. Med. J. 2010, 123, 423–430.
13. A.TaborZ.AlfirevicUpdate on Procedure-Related Risks for Prenatal Diagnosis Techniques. Fetal. Diagn. Ther. 2010, 27, 1–7.
14. R.WilsonJ.JohnsonJ.Dansereau. CEMAT Grp Randomized Trial to Assess Safety and Fetal Outcome of Early and Mid-Trimester Amniocentesis. Lancet. 1998, 351, 242–247.
15. L.JacksonJ.ZacharyS.Fowler. A Randomized Comparison of Trans-Cervical and Trans-Abdominal Chorionic-Villus Sampling. N. Engl. J. Med. 1992, 327, 594–598.
16. G.SimoniB.BrambatiC.Danesino. Efficient Direct Chromosome Analyses and Enzyme Determinations from Chorionic Villi Samples in the 1st Trimester of Pregnancy. Hum. Genet. 1983, 63, 349–357.
17. C.L.AndersonC.E.L.BrownFetal Chromosomal Abnormalities: Antenatal Screening and Diagnosis. Am. Fam. Physician2009, 79, 117–123.
18. G.CunninghamJ.C.HauthK.J.Leveno. Williams Obstetrics;McGraw-Hill: New York, 2005.
19. D.A.DriscollS.J.Gross; Professional Practice Guidelines C Screening for Fetal Aneuploidy and Neural Tube Defects. Genet. Med. 2009, 11, 818–821.
20. R.CurrierN.WuK.Van Meter. Integrated and First Trimester Prenatal Screening in California: Program Implementation and Patient Choice for Follow-up Services. Prenat. Diagn. 2012, 32, 1077–1083.
21. K.L.WilsonJ.L.CzerwinskiJ.M.Hoskovec. NSGC Practice Guideline: Prenatal Screening and Diagnostic Testing Options for Chromosome Aneuploidy. J. Genet. Counsel. 2013, 22, 4–15.
22. J.CanickPrenatal Screening for Trisomy 21: Recent Advances and Guidelines. Clin. Chem. Lab. Med. 2012, 50, 1003–1008.
23. A.GagnonR.D.WilsonF.Audibert.; Society of Obstetricians and Gynaecologists of Canada Genetics Committee. Obstetrical Complications Associated with Abnormal Maternal Serum Markers Analytes. J. Obstet. Gynaecol. Can. 2008, 30, 918–949.
24. Quest Diagnostics. Prenatal Screening and Diagnosis of Neural Tube Defects, Down Syndrome, and Trisomy 18. 2013. http://www.questdiagnostics.com/testcenter/testguide.action?dc=CFPrenatScreen
25. G.BarnardJ.KimJ.Brockel. Measurement of Choriogonadotropin by Chemiluminescence Immunoassay and Immunochemiluminometric Assay: 1. Use of Isoluminol Derivatives. Clin Chem. 1984, 30, 538–541.
26. A.DigheF.HayesJ.Khosravi. Comparison of Inhibin A Immunoassays: Recommendation for Adoption of Standardized Reporting. Clin. Chem. 2004, 50, 767–769.
27. D.A.DriscollS.J.GrossFirst Trimester Diagnosis and Screening for Fetal Aneuploidy. Genet. Med. 2008, 10, 73–75.
28. C.C.GabrielM.EchevarriaI.Rodriguez. Analysis of Quality of Nuchal Translucency Measurements: Its Role in Prenatal Diagnosis. Sci. World J. 2012, 2012, 1–8.
29. R.MaymonE.JauniauxO.Cohen. Pregnancy Outcome and Infant Follow-up of Fetuses with Abnormally Increased First Trimester Nuchal Translucency. Hum. Reprod. 2000, 15, 2023–2027.
30. M.C.HaakJ.M.Van VugtPathophysiology of Increased Nuchal Translucency: A Review of the Literature. Hum. Reprod. Update2003, 9, 175–184.
31. R.De DomenicoM.FaraciE.Hyseni. Increased Nuchal Translucency in Normal Karyotype Fetuses. J. Prenat. Med. 2011, 1, 23–26.
32. J.A.HyettIncreased Nuchal Translucency in Fetuses with a Normal Karyotype. Prenat. Diagn. 2002, 22, 864–868.
33. J.P.BestwickW.J.HuttlyN.J.WaldDistribution of Nuchal Translucency in Antenatal Screening for Down’s Syndrome. J. Med. Screen. 2010, 17, 8–12.
34. P.BennH.CuckleE.PergamentNon-Invasive Prenatal Testing for Aneuploidy: Current Status and Future Prospects. Ultrasound Obstet. Gynecol. 2013, 42, 15–33.
35. T.TeohG.RyanJ.Johnson. The Role of Fetal Karyotyping from Unconventional Sources. Obstet. Gynecol. 1996, 175, 873–877.
36. BlueChoice Health Plan of South Carolina. Chromosomal Microarray Analysis (CMA) for Developmental Delay, Autism Spectrum Disorder, Intellectual Disability (Intellectual Developmental Disorder), and Congenital Anomalies;BlueChoice Health Plan of South Carolina: Columbia, 2014.
37. BlueCross BlueShield of Alabama. Genetic Testing, Including Chromosomal Microarray (CMA) Analysis and Next Generation Sequencing Panels, for the Evaluation of Patients with Developmental Delay/Intellectual Disability or Autism Spectrum Disorder;BlueCross BlueShield of Alabama: Birmingham, 2014.
38. C.W.JiaS.Y.WangY.M.Ma. Fluorescence In Situ Hybridization in Uncultured Amniocytes for Detection of Aneuploidy in 4210 Prenatal Cases. Chin. Med. J. 2011, 124, 1164–1168.
39. S.S.HoC.ChuaL.Gole. Same-Day Prenatal Diagnosis of Common Chromosomal Aneuploidies Using Microfluidics-Fluorescence In Situ Hybridization. Prenat. Diagn. 2012, 32, 321–328.
40. B.TraskFluorescence In-Situ Hybridization-Applications in Cytogenetics and Gene-Mapping. Trends Genet. 1991, 7, 149–154.
41. K.D.TsuchiyaFluorescence In Situ Hybridization. Clin. Lab. Med. 2011, 31, 525–542.
42. M.HultenS.DhanjalB.PertlRapid and Simple Prenatal Diagnosis of Common Chromosome Disorders: Advantages and Disadvantages of the Molecular Methods FISH and QF-PCR. Reproduction2003, 126, 279–297.
43. Image Solutions (UK) Ltd. Fast Prenatal Diagnosis with Automatic Interphase FISH Scanning. 2009. http://www.hospital-int.net/article/fast-prenatal-diagnosis-automatic-interphase-fish-scanning.html
44. D.LevM.DanielyA.Zudik. Automatic Scanning of Interphase FISH for Prenatal Diagnosis in Uncultured Amniocytes. Genet. Test. 2005, 9, 41–47.
45. J.WautersE.Van AsscheA.Antsaklis. Fully Automated FISH Examination of Amniotic Fluid Cells. Prenat. Diagn. 2007, 27, 951–955.
46. D.Van OpstalM.BoterD.DeJong. Rapid Aneuploidy Detection with Multiplex Ligation-Dependent Probe Amplification: A Prospective Study of 4000 Amniotic Fluid Samples. Eur. J. Hum. Genet. 2009, 17, 112–121.
47. K.MannC.M.OgilvieQF-PCR: Application, Overview and Review of the Literature. Prenat. Diagn. 2012, 32, 309–314.
48. H.WhiteChromoQuant Version 2 QF PCR test. National Genetics Reference Laboratory (Wessex) ChromoQuant™ (version 2) In Vitro Diagnostic Test Kit for Analysis of Common Chromosomal Disorders;National Genetics Reference Laboratory: Salisbury, UK, 2005.
49. L.BrownM.AbiganiaD.Warburton. Validation of QF-PCR for Prenatal Aneuploidy Screening in the United States. Prenat. Diagn. 2006, 26, 1068–1074.
50. C.BadenasL.Rodríguez-RevengaC.Morales. Assessment of QF-PCR as the First Approach in Prenatal Diagnosis. J. Mol. Diagn. 2010, 12, 828–834.
51. S.TurrinaG.FilippiniD.De LeoRapid Prenatal Diagnosis of Common Chromosome Aneuploidies by QF-PCR: Evaluation of Two In Vitro Diagnostic Test Kits (Chromoquant and Aneufast). Forensic Sci. Int. Genet. Suppl. Ser. 2008, 1, 582–583.
52. Anonymous QF-PCR Rapid Diagnosis of Trisomy 21, 18, 13 and Sex Chromosomes Aneuploidies. http://www.aneufast.com/QF-PCR.html
53. H.ChialC.DrovdlicM.KoopmanThe Order of Nucleotides in a Gene Is Revealed by DNA Sequencing. Essentials Genet. 2009, 4, 2.
54. F.SangerA.R.CoulsonDNA Sequencing with Chain Terminating Inhibitors. Proc. Nat. Acad. Sci. U. S. A. 1977, 74, 5463–5467.
55. L.M.SmithJ.Z.SandersR.J.Kaiser. Fluorescence Detection in Automated DNA sequence analysis. Nature1986, 321, 674–679.
56. J.M.ProberG.L.TrainorF.W.Hobbs. A System for Rapid DNA Sequencing with Fluorescent Chain-Terminating Dideoxynucleotides. Science1987, 238, 336–341.
57. E.S.LanderL.M.LintonB.Birren. Initial Sequencing and Analysis of the Human Genome. Nature2001, 409, 860–921.
58. J.C.VenterM.D.AdamsE.W.Myers. The Sequence of the Human Genome. Science2001, 291, 1304–1351.
59. G.J.LiaoK.C.ChanP.Jiang. Noninvasive Prenatal Diagnosis of Fetal Trisomy 21 by Allelic Ratio Analysis Using Targeted Massively Parallel Sequencing of Maternal Plasma DNA. PLoS One2012, 7, e38154.
60. H.C.FanY.J.BlumenfeldU.Chitkara. Analysis of the Size Distributions of Fetal and Maternal Cell-Free DNA by Paired-End Sequencing. Clin. Chem. 2010, 56, 1279–1286.
61. R.W.ChiuR.AkolekarY.W.Zheng. Non-Invasive Prenatal Assessment of Trisomy 21 by Multiplexed Maternal Plasma DNA Sequencing: Large Scale Validity Study. BMJ2011, 342, c7401.
62. E.Z.ChenR.W.ChiuH.Sun. Noninvasive Prenatal Diagnosis of Fetal Trisomy 18 and Trisomy 13 by Maternal Plasma DNA Sequencing. PLoS One2011, 6, e21791.
63. R.W.ChiuK.C.ChanY.Gao. Noninvasive Prenatal Diagnosis of Fetal Chromosomal Aneuploidy by Massively Parallel Genomic Sequencing of DNA in Maternal Plasma. Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 20458–20463.
64. M.EhrichC.DeciuT.Zwiefelhofer. Noninvasive Detection of Fetal Trisomy 21 by Sequencing of DNA in Maternal Blood: A Study in a Clinical Setting. Obstet. Gynecol. 2011, 204, 205.e1–11.
65. H.C.FanY.J.BlumenfeldU.Chitkara. Noninvasive Diagnosis of Fetal Aneuploidy by Shotgun Sequencing DNA from Maternal Blood. Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 16266–16271.
66. A.B.SparksC.A.StrubleE.T.Wang. Noninvasive Prenatal Detection and Selective Analysis of Cell-Free DNA Obtained from Maternal Blood: Evaluation for Trisomy 21 and Trisomy 18. Obstet. Gynecol. 2012, 206, 319.e1–9.
67. J.SaeksDNA Sequencing and Equipment Markets. 3rd ed. 2012. Kalorama Information, New York, U.S.A.
68. T.C.GlennField Guide to Next-Generation DNA Sequencers. Mol. Ecol. Resources2011, 11, 759–769.
69. M.MarguliesM.EgholmW.E.Altman. Genome Sequencing in Microfabricated High-Density Picoliter Reactors. Nature2005, 437, 376–380.
70. D.W.BianchiR.L.ParkerJ.Wentworth. DNA Sequencing versus Standard Prenatal Aneuploidy Screening. N. Engl. J. Med. 2014, 370, 799–808.
71. H.CuckleP.BennE.Pergament. Maternal cfDNA Screening for Down Syndrome—A Cost Sensitivity Analysis. Prenat. Diagn. 2013, 33, 636–642.
72. K.G.KrulMolecular Diagnostics for Inherited Disease Testing. 2nd ed. 2004. Kalorama Information, New York, U.S.A.
73. K.SongT.J.MusciA.B.CaugheyClinical Utility and Cost of Non-Invasive Prenatal Testing with cfDNA Analysis in High-Risk Women Based on a US Population. J. Matern. Fetal Neonatal Med. 2013, 26, 1180–1185.
74. California Department of Public Health. Genetic Disease Screening Program. 2011. http://www.cdph.ca.gov/programs/centerforfamilyhealth/pages/gdspfactsheet.aspx
75. A.O.OdiboD.M.StamilioD.B.Nelson. A Cost-Effectiveness Analysis of Prenatal Screening Strategies for Down syndrome. Obstet Gynecol. 2005, 106, 562–568.
76. American Pregnancy Association. Amniocentesis. 2006. http://americanpregnancy.org/prenataltesting/amniocentesis.html
77. S.RosenThe World Market for Molecular Diagnostics. 5th ed. 2013. Kalorama Information, New York, U.S.A.
78. A.MartinApplied Biosystems Dominates the Real-Time PCR Market. 2003. http://www.prweb.com/releases/2003/04/prweb63940.htm
79. M.QuailA Tale of Three Next Generation Sequencing Platforms—Comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq Sequencers. BMC Genomics2012, 13, 341.